Moleculin Biotech, Inc. (NASDAQ:MBRX – Get Free Report) was the recipient of a large increase in short interest in the month of September. As of September 15th, there was short interest totalling 125,200 shares, an increase of 17.0% from the August 31st total of 107,000 shares. Approximately 4.6% of the shares of the company are sold short. Based on an average trading volume of 37,100 shares, the days-to-cover ratio is currently 3.4 days.
Hedge Funds Weigh In On Moleculin Biotech
An institutional investor recently raised its position in Moleculin Biotech stock. Armistice Capital LLC boosted its stake in Moleculin Biotech, Inc. (NASDAQ:MBRX – Free Report) by 5.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 156,000 shares of the company’s stock after acquiring an additional 7,505 shares during the period. Armistice Capital LLC owned 6.75% of Moleculin Biotech worth $549,000 at the end of the most recent quarter. 15.52% of the stock is owned by institutional investors and hedge funds.
Moleculin Biotech Trading Down 2.9 %
Shares of MBRX stock traded down $0.08 during trading hours on Monday, reaching $2.67. The company’s stock had a trading volume of 12,495 shares, compared to its average volume of 31,336. Moleculin Biotech has a fifty-two week low of $2.12 and a fifty-two week high of $15.75. The firm’s 50 day simple moving average is $2.60 and its 200-day simple moving average is $3.98.
Analysts Set New Price Targets
Separately, StockNews.com began coverage on Moleculin Biotech in a report on Thursday. They set a “sell” rating for the company.
View Our Latest Analysis on MBRX
Moleculin Biotech Company Profile
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
Recommended Stories
- Five stocks we like better than Moleculin Biotech
- How to buy stock: A step-by-step guide for beginners
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- Do ETFs Pay Dividends? What You Need to Know
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- Investing in Travel Stocks Benefits
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.